GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy
Korean Firm Plans Trial Start Soon
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
You may also be interested in...
Webinar Recording: Coronavirus Pharma Industry Impact In China, Korea And Japan
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
GC Pharma Preps For Life After Sale Of North American Subsidiaries
South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.
How Was Korea Different In Handling COVID-19 Situation?
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.